{"DataElement":{"publicId":"4474280","version":"1","preferredName":"Person Human Immunodeficiency Virus Highly Active Antiretroviral Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable response regarding whether the patient is HIV positive and receiving combination antiretroviral therapy that meets the requirements for participation in a clinical trial.","longName":"HIV_POS_XRET_TX_COD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"3179417","version":"1","preferredName":"Person Human Immunodeficiency Virus Highly Active Antiretroviral Therapy Clinical Trial Eligibility Criteria","preferredDefinition":"information related to a person being positive for Human Immunodeficiency Virus, a cytopathic retrovirus, and being treated with antiretroviral therapy, drug therapy which targets retrovirus function, as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3179415v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3179415","version":"1","preferredName":"Human Immunodeficiency Virus Highly Active Antiretroviral Therapy Clinical Trial Eligibility Criteria","preferredDefinition":"Human immunodeficiency virus. Species of LENTIVIRUS, subgenus primate lentiviruses (LENTIVIRUSES, PRIMATE), formerly designated T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). It is acknowledged to be the agent responsible for the acute infectious manifestations, neurologic disorders, and immunologic abnormalities linked to the ACQUIRED IMMUNODEFICIENCY SYNDROME.:Drug therapy which targets retrovirus function by multiple mechanisms.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C14219:C16165:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Human Immunodeficiency Virus","conceptCode":"C14219","definition":"The virus isolated and recognized as the etiologic agent of AIDS. HIV-1 is classified as a lentivirus, a subtype of retroviruses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Highly Active Antiretroviral Therapy","conceptCode":"C16165","definition":"Drug therapy which targets retrovirus function by multiple mechanisms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9892AA8D-A783-8711-E040-BB89AD436ABE","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-29","modifiedBy":"ONEDATA","dateModified":"2010-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9892AA8D-A794-8711-E040-BB89AD436ABE","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-29","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876425","version":"1","longName":"Laboratory Data (including serologic/viral status)","context":"Theradex"}]},{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"10000083","version":"1","longName":"Physical & Concomitant Requirements","context":"Theradex"},{"publicId":"10000707","version":"1","longName":"Laboratory Data (including serologic/viral status)","context":"Theradex"}]},{"publicId":"5999742","version":"1","longName":"CRF CDEs","context":"CITN","ClassificationSchemeItems":[{"publicId":"5999747","version":"1","longName":"Eligibility CDEs","context":"CITN"}]}],"AlternateNames":[{"name":"CITN","type":"USED_BY","context":"CITN"}],"ReferenceDocuments":[{"name":"Theradex - 1","type":"Alternate Question Text","description":"Is patient HIV positive with inadequate CD4 counts or is on combination antiretroviral therapy with strong CYP3A4 effects?","url":null,"context":"Theradex"},{"name":"Is patient HIV-positive and o","type":"Preferred Question Text","description":"Is patient HIV-positive and on combination antiretroviral therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"If patient is Human Immunodeficiency Virus (HIV) positive, are all of the following criteria met: must be stable on their anti-retroviral regimen, healthy from an HIV perspective, have a CD4 count of greater than 250 cells/mcL and must not be receiving prophylactic therapy for an opportunistic infection?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"If patient is HIV-positive and on antiretroviral therapy does patient meet the following criteria: Cancer as the only AIDS-defining condition; CD4 cell count greater than or equal to 250, Treatment sensitive HIV and prospects for long term survival on the basis of HIV disease alone and is willing to take anti-HIV therapy that will have minimal potential for pharmacokinetic interactions with GDC-0449?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"If patient is HIV-positive, patient is on a stable dose of highly active antiretroviral therapy (HAART), CD4 counts are greater than 350 and viral load is undetectable?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"If patient is HIV+, is CD4+ count greater than or equal to 300/Î¼L, viral load is undetectable and patient is currently receiving Highly Active Antiretroviral Therapy (HAART)?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"If patient has tested positive for HIV, is CD4 count adequate (>350/ul), is on a stable regimen of HAART with no detectable or minimal viral burden, and has no active infections?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Prior to leukemia diagnosis, was HIV disease uncomplicated as evidenced by: the  CD4+ T-cell counts were generally in excess of 300/mm3; HIV viral loads were less than 200 copies/ml if on anti-HIV therapy; the HIV is newly diagnosed or there is no history of using anti-HIV therapy, there are no AIDS defining conditions or other HIV-related symptoms; Zidovudine is not allowed as part of the anti-HIV therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Is patient HIV-positive and on antiretroviral therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"If patient is a healthy HIV-infected patient, is CD4+ count greater than or equal to 250/mm3, patient is not on antiretroviral therapy affecting p450 metabolism and HIV viral loads are undetectable by standard clinical tests?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"If patient has concurrent HIV infection, is patient non-compliant with 3 or more drug anti-retroviral regimen and virus load is more than 50 copies/ml and CD4 count is less  than 250 cells/ml, and patient has concurrent opportunistic infection or other malignancy?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"If patient is infected with HIV, does patient meet all of the criteria per section 3.1.11 of the protocol?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"If patient is a healthy HIV-infected patient, is CD4+ count greater than or equal to 250/mm3 and HIV viral loads are undetectable by standard clinical tests?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"If patient is HIV+, is CD4+ T-cell greater than or equal to 250/mm3, HIV is sensitive to antiviral therapy, patient is not taking Zidovudine, long term survival is anticipated on the basis of HIV alone were it not for the lymphoma and there is no concurrent AIDS-defining illness other than the lymphoma?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Is patient HIV-positive and on combination antiretroviral therapy with strong inducers of CYP3A4?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Prior to leukemia diagnosis, HIV disease was uncomplicated as evidenced by: the  CD4+ T-cell counts were generally in excess of 300/mm3; HIV viral loads were less than 200 copies/ml if on anti-HIV therapy; if the HIV is newly diagnosed or there is no history of using anti-HIV therapy, there are no AIDS defining conditions or other HIV-related symptoms; Zidovudine is not allowed as part of the anti-HIV therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Is patient HIV-positive and on combination antiretroviral therapy with strong inducers or inhibitors of CYP3A4?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"If patient has known active HIV infection, does patient have chronic HIV and a CD4 greater than 250, undetectable viral load by PCR, no opportunistic infection, and is on a stable regimen of HAART therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"If patient is positive for human immunodeficiency virus (HIV) is patient on a stable regimen of highly active anti-retroviral therapy (HAART), has no requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections and CD4 count is above 250 cells/mcL, and has an undetectable HIV viral load on standard PCR-based tests?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Is patient HIV-positive and receiving antiretroviral therapy that is a strong inducer of CYP3A4?\r\n","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Is patient known to be HIV-positive and on combination antiretroviral therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Is patient immunocompromised, including those HIV-positive patients on combination antiretroviral therapy?","url":null,"context":"Theradex"},{"name":"CITN-1","type":"Alternate Question Text","description":"Patient is on antiretroviral therapy and there are minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment.","url":null,"context":"CITN"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"If patient is HIV-positive and on combination antiretroviral agents that are strong CYP3A4 inhibitors or inducers, is patient unwilling or unable to change to antiretroviral therapies without such interactions?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"Is patient HIV-positive and receiving combination antiretroviral therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 24a","type":"Alternate Question Text","description":"If patient is HIV-positive and on an effective cART regimen, there are no known pharmacokinetic interactions of the cART agents with olaparib, they have been on this regimen for greater than or equal to 4 weeks with an HIV viral load of less than 200 copies/mL and CD4+ count greater than or equal to 100 cells/uL; CD4+ count less than 200 cells/uL, requires CD4+ CD8+ ratio greater than 0.4?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Does patient with human immunodeficiency virus require HAART treatment due to unknown drug-drug interactions?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Is patient HIV-positive and on combination antiretroviral therapy with strong inducers or inhibitors of CYP3A4?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"If patient is HIV-Infected, is patient on effective anti-retroviral therapy with undetectable viral load within 6-months?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"If patient is HIV positive, is patient receiving HIV medications considered to be inhibitors or inducers of CYP3A4?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Is patient HIV-positive, with CD4 counts less than 500 cells/mm3 in the past 6 months and requires CYP3A4-interactive antiretroviral therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"If patient is Human Immunodeficiency Virus (HIV)-infected, is patient receiving effective antiretroviral therapy, with undetectable viral load within 6 months?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Has patient been on stable ART therapy regimen for at least 4 weeks with no intention to change the regimen within 8 weeks following study entry and will continue on the protocol accepted ART as long as they are receiving XL184 (cabozantinib)?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"If patient is Human Immunodeficiency Virus (HIV)-positive, is patient on combination antiretroviral therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"If patient is Human Immunodeficiency Virus (HIV) positive, are all of the following eligibility requirements met: 1) Must be stable on their anti-retroviral regimen, and healthy from an HIV perspective. 2) Have CD4 count of greater than 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and must not have had a CD4 count less than 200 cells/mcl over the past 2 years, unless it was deemed related to THE CANCER AND/OR CHEMOTHERAPY-induced bone marrow suppression. 3) Have an undetectable viral load and a CD4 count greater than or equal to 250 cells/mcL within 7 days of enrolment. 4) Must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"If HIV-positive, has patient been on effective anti-retroviral (ART) therapy for at least 3 months prior to enrollment, with persistent KS affecting quality of life due to either T1 disease or T0 disease with inadequate disease regression on ART alone?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"If HIV-positive, is patient on antiretroviral therapy (ART) greater than or equal to 4 weeks and with evidence of viral suppression defined as HIV viral load less than 400 copies/mL, has no major (e.g. AIDS-defining) opportunistic infections within the last 6 months with the exception of the following which will be allowed; Esophageal candidiasis treated within last 6 months or currently improving with antifungal treatment, Oral and/or genital HSV treated within the last 6 months or currently improving with antiviral treatment, and Mycobacterium avium infection in last 6 months or that has been treated for at least 1 month?","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0230001B-059D-B07D-E050-BB89AD432E50","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"SOKKERL","dateModified":"2021-03-25","changeDescription":"9343_Theradex_ghd_09.03.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}